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ABSTRACT
Objectives: To estimate the cost-effectiveness of sorafenib (Nexavar,
Bayer, Leverkusen, Germany) versus best supportive care (BSC) for
second-line treatment of advanced renal cell carcinoma from the perspec-
tive of the UK National Health Service.
Methods: A decision analytic model was developed to estimate the cost-
effectiveness of sorafenib. The clinical effectiveness of sorafenib versus
BSC was taken from a recent randomized phase III trial. Utility values
were taken from a phase II trial of sunitinib, using EQ-5D tariffs. Cost
data were obtained from published literature and were based on current
UK practice. The effect of parameter uncertainty on cost-effectiveness was
explored through extensive one-way and probabilistic sensitivity analyses.
Results: Compared to BSC, sorafenib treatment resulted in an incremental
cost per quality-adjusted life year (QALY) gained of £75,398, based on an
estimated mean gain of 0.27 QALYs per patient, at a mean additional cost
of £20,063 (inﬂated to 2007/2008). The probability that sorafenib is
cost-effective compared to BSC at a willingness to pay threshold of
£30,000 per QALY is 0.0%. In sensitivity analysis, estimates of cost per
QALY were sensitive to changes in the clinical effectiveness parameters,
and to health state utilities and drug costs.
Conclusions: Sorafenib has been shown to be clinically effective compared
to BSC, offering additional health beneﬁts; however, with a cost per QALY
in excess of £70,000, it may not be regarded as a cost-effective use of
resources in some health-care settings.
Keywords: cost-effectiveness, cost-utility, decision analytic modeling,
Nexavar, renal cell carcinoma, sorafenib.
Introduction
Renal cell carcinoma (RCC) is a highly vascular type of kidney
cancer, often asymptomatic until it reaches a late stage. Meta-
static spread may involve the lymph nodes, lung, bones, liver,
brain, and other organs [1]. In England and Wales, kidney cancer
is the 8th most common cancer in males and the 14th most
common cancer in females [2]. In 2004, there were 5745 regis-
trations of newly diagnosed kidney cancer in England and Wales
[2,3]. The prognosis following diagnosis of metastatic RCC is
poor. In England and Wales, approximately 90% of people diag-
nosed with stage IV RCC die within 5 years of diagnosis, where
tumor stage, increasing in severity from I to IV, is based on the
combination of tumor size and extent of spread from the kidneys
[1]. Until recently, treatment options for metastatic RCC have
comprised radical nephrectomy and immunotherapy (i.e.,
interferon-a the UK [1]). Nevertheless, a number of new phar-
macological therapies (sunitinib, bevacizumab, sorafenib, and
temsirolimus) have been licensed for treatment of RCC, across
speciﬁc indications. These drugs offer health beneﬁts to patients
with RCC [1], but due to their relatively high cost, their cost-
effectiveness may be questioned [4]. In this article, we present
cost-effectiveness analysis for one of these new drugs, sorafenib,
compared with best supportive care (BSC).
Sorafenib is an orally active bi-aryl urea, small molecule
inhibitor of various tyrosine kinase receptors licensed for ﬁrst-
line use in individuals who are not suitable for treatment with
interferon-a and as second-line therapy in those in whom treat-
ment with cytokine-based immunotherapy has failed. A recent
phase III randomized trial, reported by Escudier et al. (2007) [5],
demonstrated the survival beneﬁt of sorafenib tosylate over BSC
as second-line therapy. The median age of patients in this trial
was 58 years.
The cost-effectiveness of treatment with sorafenib in this
patient group has not previously been published, although Bayer,
the manufacturer of sorafenib, recently made a submission to
National Institute for Health and Clinical Excellence (NICE),
which included a cost-effectiveness analysis for sorafenib com-
pared to BSC [4]. The decision analytic model, and subsequent
cost-effectiveness analysis, presented here formed part of the
independent assessment report submitted to NICE (by the
authors) and were used to inform the NICE Health Technology
Appraisal process.
Methods
Model Structure
A Markov-type decision analytic model was developed to model
disease progression in RCC and the treatment effectiveness of
sorafenib versus BSC. Using this model, we have estimated the
cost-effectiveness of sorafenib versus BSC in peoplewith advanced
RCC. The model uses survival analysis to consider progression of
RCC in a cohort of patients over time. The model was written in
Microsoft Excel (Microsoft Corporation, Redmond, WA). The
structure of the model was informed by a review of the available
literature, clinical guidelines for treatment of RCC, and expert
opinion on the clinical progression of the disease [1].
At any time, a patient is assumed to be in one of three health
states: progression-free survival (PFS), progressive disease (PD),
and death. Patients move between states during each cycle. All
patients enter the model in PFS, having been diagnosed with
advanced/metastatic RCC. Patients remain in PFS until disease
progression or death. Once patients enter PD, they remain there
until death. The model uses estimates of effectiveness, costs and
health state values against these health states to model progres-
sion of disease, and cost-effectiveness over time. The model uses
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a 10-year time horizon (by which time virtually all simulated
patients are dead), and a 6-week model cycle. This structure is
simple but appropriate for capturing the disease progression of
RCC. Future costs and beneﬁts are discounted at 3.5% per year
[6].
For both sorafenib and BSC, separate Weibull curves are used
to predict the number of patients alive over time and the number
of patients in PFS over time. The number of patients in progres-
sive disease is then estimated as the number alive minus the
number in PFS. The plots of log(cumulative hazard) versus
log(time) for BSC and sorafenib for PFS were not parallel, indi-
cating that the proportional hazards assumption did not hold.
Therefore, to model disease progression for both treatments,
Weibull curves were ﬁtted separately to the PFS and overall
survival (OS) Kaplan–Meier data reported by Escudier et al.
(2007) [5]. Weibull curves were ﬁtted to the survival data by
regressing log(–log(S(t)) against log(t), where S(t) is the survival
function at time t [7]. This regression is obtained by taking
double logs of both sides of the Weibull survival function
S(t) = exp(–atg). Regression usefully yields estimates of the uncer-
tainty in and correlation between parameters l and g, which are
used to model uncertainty in the curve ﬁts in the probabilistic
sensitivity analysis. The Weibull curves ﬁtted the Kaplan–Meier
data well, as measured by the R2 statistic: 96% for BSC
PFS, 99% for BSC OS, 100% for sorafenib PFS, and 99% for
sorafenib OS.
Given the number of patients for each treatment in each of
the health states at each model cycle, the total discounted costs
and beneﬁts were calculated as follows. The cost estimated at
each cycle was calculated as the sum over the PFS and PD health
states of the product of the number of patients in the state and
the cost incurred in that state over the cycle. The total discounted
cost was calculated as the sum over all cycles of the discounted
costs in each cycle. The total discounted QALYs was calculated
similarly. The QALYs in each cycle were calculated as the sum
over the PFS and PD health states of the products of the number
of patients in the state and the utility in that health state divided
by the number of cycles per year. Half-cycle corrections were
applied by calculating the average number of patients over each
model cycle in each health state.
Clinical Effectiveness
Clinical effectiveness data were taken from the randomized clini-
cal trial (RCT) reported by Escudier et al. (2007) [5], a multina-
tional, multicenter, phase III, double-blind, randomized,
controlled clinical trial. Given that this was the only phase III
trial of sorafenib in the appropriate patient population, this was
the only choice of effectiveness evidence. In particular, an
extended evidence network or mixed treatment comparison was
not relevant. The Weibull curves ﬁtted to PFS and OS for sor-
afenib and BSC are shown in Figure 1. They are derived from the
Weibull parameters shown in Table 3. Clinical results and patient
enrollment are described in detail elsewhere [5]. In brief, 903
patients with advanced RCC, resistant to standard therapy, were
randomized to receive either sorafenib (451 patients) or placebo
(452 patients). Most patients (82%) had previously received
cytokine-based therapy (interferon-a or interleukin-2). Virtually
all (99%) patients had clear-cell RCC, and 93% had had a prior
nephrectomy. Fifty-one percent of patients were assessed as
having low Memorial Sloan-Kettering Cancer Center (MSKCC)
prognostic risk, 49% intermediate risk, and 0% poor risk [1].
Sorafenib (400 mg, orally) was taken twice daily. Sorafenib was
administered until disease progression, symptomatic deteriora-
tion, or intolerable adverse events. In April 2005, on the basis of
the ﬁrst PFS analysis, a decision was made to offer sorafenib to
patients who were assigned to placebo. A ﬁrst analysis of OS was
performed at the start of treatment crossover, in May 2005.
Sorafenib was signiﬁcantly beneﬁcial compared to BSC for both
PFS and OS: For PFS, the investigator-assessed hazard ratio (HR)
was 0.51 (95% conﬁdence interval [CI]: 0.43–0.60), and for OS,
immediately before crossover of patients, the HR was 0.72 (95%
CI: 0.54–0.94) [5].
Health State Utilities
We used health state utilities of 0.76 (s.e. 0.03) for PFS and 0.68
(s.e. 0.04) for PD, reported in Thompson-Coon et al. (2008) [1],
which are derived from a phase II single-arm trial of sunitinib for
patients on second-line treatment, reported by Motzer et al.
(2006) [8], from UK EQ-5D tariffs, although the authors do not
report the EQ-5D data used to estimate the health state values.
These values were used, as opposed to other available data [9], as
they were derived from a patient population receiving second-
line treatment of advanced RCC.
Resource Use and Costs
The perspective for costs is that of the UK National Health
Service (NHS) and Personal Social Services. There is an absence
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Figure 1 Weibull curves ﬁtted to best supportive
care (BSC) and sorafenib progression-free survival
(PFS) and overall survival (OS) Kaplan–Meier data.
Data taken from Escudier et al. (2007) [5].
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of published data to inform on the costs associated with treat-
ment of RCC. Assumptions were based on guidelines outlining
current practice and information provided by clinical experts (see
Acknowledgments). The price of sorafenib is £2980.47 per
200 mg 112-tablet pack [10] which, at a dose of 400 mg twice
per day, gives a cost of £4471 per patient per 6-week model cycle.
We have assumed that the ﬁrst pack of sorafenib is free to the
NHS, as recently agreed by the manufacturer of sorafenib (Bayer)
and UK Department of Health [10]. Because compliance with
treatment was not reported in the clinical trial [5], we have
assumed 100% compliance with sorafenib in the base-case. Nev-
ertheless, as the total amount of drug administered is likely to be
lower than this due to patient withdrawals and dose reductions,
we have varied the dose intensity (deﬁned as the amount of drug
administered as a proportion of the amount that would have
been administered if there had been no patient withdrawals or
dose reductions) in the sensitivity analysis. This is in line with the
use of effectiveness data collected on an intention-to-treat basis.
Within the model, nondrug costs include the cost of medical
management (computed tomography scans, monitoring, blood
tests) in PFS, BSC in PD, and death (used in the sensitivity analysis)
(Table 1). There is no cost for administration of sorafenib because
it is taken orally. All costs were inﬂated to 2007/2008 values using
the Hospital & Community Health Services Pay and Prices Index
[11]. The costs of medical management are small relative to the
cost of acquisition of sorafenib. We considered only costs associ-
ated with grade 3 or 4 adverse events [12] because these are
expected to incur NHS costs. Hypertension was the only adverse
event whose incidence differed signiﬁcantly between treatment in
the pivotal trial [5]. For the treatment of hypertension, we
assumed two GP visits per year (cost per visit = £35 [11]), two
district nurse visits per year (cost per visit = £25 [11]), and medi-
cation for hypertension (cost per year = £246 [13]), at a total cost
of £367 per year. We assumed treatment for hypertension contin-
ues for the duration of PFS. Given an incidence of hypertension of
4% per patient with sorafenib, we estimate the total adverse event
cost per patient per year for sorafenib as £11. For BSC, the
incidence of hypertension was zero, giving the total adverse event
cost per patient per year as zero.
Sensitivity Analyses
One-way sensitivity analyses and probabilistic sensitivity analy-
ses were performed by varying effectiveness, utility, and costs
parameters. One thousand simulations of the model were run
in the probabilistic sensitivity analysis. For the probabilistic
sensitivity analysis, utilities followed beta distributions [14] and
nondrug costs followed gamma distributions [14]. For simplic-
ity, adverse event costs were assumed deterministic given that
they are so small. We imposed the constraint that at any time
t, the number of patients in PFS was limited to the number of
patients alive. The two parameters of the Weibull distribution,
ln(l) and g, for baseline BSC PFS and separately for OS were
drawn from bivariate normal distributions, using the method of
Cholesky matrix decomposition. This was repeated indepen-
dently for the Weibull parameters for sorafenib. The variance–
covariance matrices used in the matrix decomposition were
estimated from linear regression of ln(–lnS(t)) against ln(t),
described above, where S(t) is the survival function at time t.
We acknowledge that this method does not allow for all uncer-
tainty in the treatment effect. If individual patient level data
were available, we would have estimated the expected values
and uncertainty in the Weibull parameters by the method of
maximum likelihood. Nevertheless, given that individual
patient data were not available, and given that the curves
for sorafenib and BSC were ﬁtted independently, we know of
no way of allowing for the full uncertainty in the treatment
effect.
Results
The primary outcome of the analysis was the cost per QALY
gained. For sorafenib compared to BSC, we estimate an incre-
mental gain of 0.27 QALYs, at an additional cost of £20,063 per
patient, giving an incremental cost-effectiveness ratio (ICER) of
£75,398 per QALY (Table 2). Incremental costs (Table 2) are
heavily inﬂuenced by the cost of sorafenib and, to a far lesser
extent, by the costs of medical management and BSC in progres-
sive disease.
The cost per QALY is particularly sensitive to the curve ﬁts
for OS and, to a lesser extent, to the curve ﬁts for PFS (Table 3).
The cost-effectiveness of sorafenib is also sensitive to the cost of
sorafenib, the dose intensity of sorafenib, and the choice of
utilities. The ICER is only marginally inﬂuenced by the other
parameters, including discounting, time horizon, and nondrug
costs.
Table 1 Nondrug costs
Progression-free survival (PFS) medical management
Progressive Disease (PD)
medical management
BSC sorafenib BSC and sorafenib
Consultations per month 1 GP 1 consultant outpatient 1 GP, 1.5 community nurse
Tests 1 CT scan per 6 months,
blood tests monthly
1 CT scan per 3 months,
blood tests monthly
None
Other‡ None None Pain medication (morphine
sulphate) daily¶
Cost per 6-week model cycle (s.e.)* £81 (£3) £223 (£9) £435 (£22)#
Unit costs (inﬂated to 2007/8):
Consultant, outpatient visit: £107 per visit [20], £111 inﬂated to 2007/8 (Specialty code 370).
GP Visit: £34 per visit [11] £35 inﬂated to 2007/8.
Community Nurse visit: £83 per visit [20], £86 inﬂated to 2007/8. Band 2—Palliative / Respite Care :Adult : Face to Face Total Contacts NHS.
CT Scan: £135 per scan [21] £140 inﬂated to 2007/8 (Specialty code RBD1. “Band D1 – CT”.)
Haematology, blood tests [Excluding Anti-Coagulant Services]: £3 per test [20], £3 inﬂated to 2007/8.
¶Morphine Sulphate £5 per pack, 1 dose per day. (Non-proprietary); 1 mg/mL, net price 50-mL vial preﬁlled syringe £5.00 per pack [22].
Notes:
#As a sensitivity analysis, we assumed a cost of £937 per month for treatment in PD for hospital and hospice care, based on a study of costs of managing women with stage IV breast cancer
in the UK [23]. Mostly medication, scans, tests, hospitalization, outpatient visits.
‡In the base case, we assumed no cost of death.As a sensitivity analysis, we assumed a cost of £3923, taken from Coyle et al. (1999) [24], averaged over hospital and hospice stays = £2701,
revalued to 2007/8.
*Standard errors (s.e.) were calculated from the interquartile ranges and number of data submissions given in [20] and [21], except for the cost taken from [11], the cost of BSC in PD, which
was estimated by assuming the average ratio of standard error to mean, 0.06, over all other costs.
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At a willingness to pay threshold of £30,000 per QALY, the
probability that sorafenib is cost-effective compared to BSC is
0.0% (Figs. 2 and 3).
Discussion
Treatment of patients with advanced RCC with sorafenib has
been shown to be clinically effective [5]. Nevertheless, due to the
balance of costs and beneﬁts, the cost-effectiveness of sorafenib
may be questioned [4]. The result here, showing £75,398 QALY
is above the levels of cost-effectiveness usually regarded as offer-
ing value for money in the UK NHS [6] and in other international
settings [15–17]. Cost-effectiveness estimates are most sensitive
to changes in effectiveness data for OS, which is also rather
uncertain. At the time of patient crossover from BSC to sor-
afenib, the OS data from the pivotal RCT [5] are fairly immature,
with approximately 38% of patients receiving BSC still alive.
Nonetheless, even assuming an optimistic scenario, by applying
the lower 95% ICER conﬁdence value reﬂecting uncertainty in
the curve ﬁt for OS for sorafenib, the estimated cost per QALY is
£64,156 (Table 3) and remains at a level that may not be
regarded as offering value for money.
Sorafenib is an orphan drug, and this may be a further rel-
evant consideration for some policymakers [18]. Other poten-
tially relevant issues that sit outside the cost-effectiveness
framework include the poor prognosis for patients with RCC
and the absence of other effective treatment options.
There are limitations with the analysis presented here due to
the scarcity of data available to estimate cost-effectiveness. We
acknowledge that there is only one published RCT of sorafenib
compared with BSC in people with RCC [5]. Although this is a
large, good quality trial, any biases within the trial will be
reﬂected in the cost-effectiveness analysis presented. Further-
more, given that virtually all (99%) patients in the trial had
clear-cell RCC, and nearly all (93%) had had a prior nephrec-
tomy, it is unclear whether our cost-effectiveness results can be
applied to patients with non-clear-cell RCC and/or patients
without prior nephrectomy.
There is an absence of published data to inform on the costs
associated with treatment of RCC, and in the analysis, we have
used data based on UK clinical practice. Nevertheless, we can see
from Table 2 that cost-effectiveness is largely determined by the
cost of sorafenib. Other items of resource use have less impact on
estimates of cost-effectiveness. Furthermore, given an absence of
data on the disutility due to the adverse event of hypertension,
this quantity was set to zero. More generally, as is common in
health technology assessment, we have access only to secondary
summary data, not individual patient data, to model treatment
efﬁcacy. Individual patient data on treatment effectiveness may
Table 2 Base-case discounted per patient mean costs and effects
BSC Sorafenib
Sorafenib
vs. BSC
Life years 1.30 1.66 0.37
QALYs 0.91 1.18 0.27
Time on treatment n/a 0.55 n/a
Drug cost £0 £18,599 £18,599
Drug admin £0 £0 £0
Medical management* £248 £1,079 £830
BSC in PD £3,549 £4,183 £634
Total costs £3,797 £23,860 £20,063
Cost/LYG £54,565
Cost/QALY £75,398
*CT scans, monitoring, blood tests.
BSC, best supportive care; CT, computed tomography; LYG, live years gained; PD, progressive
disease; QALYs, quality-adjusted life years.
Table 3 Results of sensitivity analysis
Base-case Sensitivity analysis ICERSorafenib vs. BSC
Base-case n/a n/a £75,398
General
Time horizon 10 years 5 years £77,822
Discounting 3.5% p.a. costs and beneﬁts 0% p.a. costs and beneﬁts £71,028
Effectiveness
PFS BSC l = 0.262, g = 0.943 l, g multivariate normal £74,859–£76,038‡
OS BSC l = 0.013, g = 1.502 l, g multivariate normal £65,479–£84,852‡
PFS sorafenib l = 0.057, g = 1.433 l, g multivariate normal £71,463–£78,937‡
OS sorafenib l = 0.013, g = 1.399 l, g multivariate normal £64,156–£86,734‡
Costs
Cost of sorafenib £2,980.47 per 200 mg 112-tablet pack £2,235.35 (25% reduction) £57,924
£1,788.28 (40% reduction) £47,440
Cost associated with death £0 £3,923 £75,211
BSC cost in PD (per 6-week cycle) £435 £1,297* £80,124
Cost of monitoring, outpatient
costs (per 6-week cycle)
£154 sorafenib, £48 BSC £0 £73,179
£308 £77,617
Cost CT scan (per 6-week cycle) £65 sorafenib, £32 BSC £0 £74,603
£130 £76,193
AE cost £0 BSC, £11 sorafenib £0 both treatments £75,367
Dose intensity 100% sorafenib 80% sorafenib £61,419
Utilities
Utilities 0.76 PFS, 0.78 PFS, 0.70 PD† £73,399
0.68 PD PFS utility 0.70 (lower 95% CI) £78,825
PFS utility 0.81 (upper 95% CI) £72,569
PD utility 0.61 (lower 95% CI) £79,046
PD utility 0.76 (upper 95% CI) £71,898
PFS utility 0.70, PD utility 0.61 (both lower 95% CIs) £82,821
*Based on Remak & Brazil (2004) [23].
†Taken from Motzer et al. (2007) RCT [25].
‡95% conﬁdence interval for ICER based on 1000 simulations, varying each curve one at a time.
AE, adverse event; BSC, best supportive care; CI, conﬁdence interval; CT, computed tomography; ICER, incremental cost-effectiveness ratio; OS, overall survival; PD, progressive disease; PFS,
progression-free survival; RCT, randomized clinical trial.
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yield a more accurate assessment of cost-effectiveness and allow
modeling of all uncertainty in treatment effectiveness, but this
information is unpublished. In particular, we have estimated PFS
and OS for BSC and sorafenib by ﬁtting Weibull curves to
Kaplan–Meier data. Nevertheless, it is preferable to ﬁt Weibull
curves using the method of maximum likelihood using individual
patient data [19].
Furthermore, on speciﬁc issues, we have assumed that the
treatment effectiveness of BSC and sorafenib in normal clinical
practice will be similar to the values obtained in the pivotal RCT
[5]. We have assumed that our estimate of the dose intensity of
sorafenib of 100% is approximately equal to that experienced in
the RCT. Indeed, this is consistent with the observation that only
6%of patients receiving sorafenib in the RCThad dose reductions
[1]. If, however, the dose intensity of sorafenib in the RCT was
lower than 100%, then sorafenib would appear more cost-
effective. In the probabilistic sensitivity analysis, we have not
allowed for uncertainty in the dose intensity of sorafenib, due to
lack of evidence. Inclusion of uncertainty in this parameter would
lead to greater uncertainty in the estimates of cost-effectiveness.
The effectiveness data in this study were taken from a multi-
national clinical trial [5] and the cost data were based on practice
relevant to the UK NHS. Therefore, our cost-effectiveness results
are applicable to other countries only if the costs are similar to
those in other countries. Nonetheless, the modeling framework
used here could be easily adapted, with relevant cost data, to
inform on health policy decisions in other countries.
This is the ﬁrst fully published economic cost-effectiveness
analysis of sorafenib for treatment of RCC. It has been produced
by an independent research team, with clinical support, and was
informed by a comprehensive systematic review of the effective-
ness literature [1]. In conclusion, we ﬁnd that although sorafenib
signiﬁcantly improves PFS and OS compared to BSC for second-
line treatment of patients with RCC, treatment with sorafenib
may not be regarded as a cost-effective use of resources in some
health-care settings.
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Figure 2 Cost-effectiveness acceptability curve
for sorafenib versus best supportive care. The
median is shown by the dotted line.
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Figure 3 Simulations of mean incremental total
costs versus beneﬁts for sorafenib versus BSC.
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